SK Chemicals and GC Pharma are competing in the private 4-valent influenza (flu) vaccine market with an external banding of 200 billion won, the survey showed. SK Chemical's SKY Cellflu Quardrient and GC Flu Quardrient ranked first and second in the private distribution flu vaccine for the past three years (2018, 2019, 2020), with performances of "11.3 billion won, 13.1 billion won, and 63.8 billion won," "7.7 billion won, 12.4 billion won, and 51.5 billion won," respectively.

However, in the case of last year, it is difficult to compare sales absolutely because SK Chemical placed seasonal flu production as a subordinate priority due to CMO issues of the COVID-19 vaccine. The growth of Boryung Biopharma Fl